San Antonio Breast Cancer Symposium (SABCS) 2020

08 December 2020 - 12 December 2020

Adding chemo to endocrine therapy may benefit premenopausal women with early breast cancer

Roshini Claire Anthony, 20210125180001

The addition of chemotherapy to endocrine therapy improved invasive disease-free survival (IDFS) in premenopausal women with lymph node-positive early stage hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer with recurrence score ≤25, according to early results of the phase III SWOG S1007 RxPonder* trial presented at SABCS 2020. However, the benefits did not appear to extend to postmenopausal women.

Breast cancer survivors less likely to get pregnant, but babies often healthy if they do

Pearl Toh, 20210114150000

While breast cancer survivors of childbearing age are less likely to get pregnant than the general population, most of them who do become pregnant deliver healthy babies without detrimental outcomes on their long-term survival, according to a large meta-analysis presented at the SABCS 2020 Congress.

Physicians may underestimate symptoms in breast cancer patients undergoing radiotherapy

Roshini Claire Anthony, 20210107180001

Physicians may often underestimate symptoms of pain, oedema, fatigue, and pruritus in patients undergoing radiotherapy for breast cancer, according to a study presented at SABCS 2020.

Omitting radiotherapy: An option after breast-conserving surgery in older patients?

Pearl Toh, 20201229141000

Omitting radiotherapy after breast-conserving surgery in older patients with hormone receptor (HR)-positive breast cancer who were also receiving appropriate systemic therapy did not impact overall survival (OS) at 10 years, even though the rate of local recurrence was higher than those who had radiotherapy, according to the PRIME* II study presented at SABCS 2020.

Mindfulness meditation cuts depressive symptoms in young breast cancer survivors

Yoga reduces depressive symptoms in young breast cancer survivors

Pearl Toh, 20201220150000

Behavioural interventions are effective in mitigating depressive symptoms in young survivors of breast cancer, according to a study presented at SABCS 2020. In particular, mindfulness meditation also improves other outcomes related to well-being such as fatigue and sleep disturbance.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!

Ivermectin-doxycycline combo superior to monotherapy in severe rosacea

Stephen Padilla, 31 Jan 2020

The combination of ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (DMR) delivers faster responses, better response rates and greater satisfaction compared with monotherapy in patients with severe rosacea, a recent study has shown.

Original New Drug Application Approvals by US FDA (16 - 31 May 2020)

02 Jun 2020

New drug applications approved by US FDA as of 16 - 31 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

FDA-approved drug ivermectin kills SARS-CoV-2 in vitro

Stephen Padilla, 08 Apr 2020

An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.